Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

This study investigated the potential of nutmeg-derived phytochemicals as anti-alopecia agents using molecular docking and simulations, finding that geranylgeraniol exhibited significant binding stability and potential efficacy against androgenetic alopecia comparable to finasteride and superior to minoxidil.

This meta-analysis found that among topical OTC treatments for male androgenetic alopecia, minoxidil 5% applied twice daily was the most effective in increasing total hair density over 24 weeks.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study observed that among patients starting Semaglutide therapy at 0.25-2mg weekly, approximately 0.80-0.83% reported non-scarring hair loss within six months, suggesting the drug does not significantly increase hair loss risk.

This study found that palmoplantar pustulosis patients exhibited oral dysbiosis, particularly among those with pustulotic arthro-osteosis, as compared to healthy controls.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This study found a notably high prevalence of metabolic syndrome among apparently healthy individuals in Pakistan, with high triglycerides, low HDL, and central obesity identified as significant risk factors.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This review observed limited evidence of clinically significant benefits from treatments for acute central serous chorioretinopathy, which often resolves spontaneously, but identified PDT and micropulse laser as the most promising for further trials.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

In this study, MSC-scaffold combinations were found to significantly enhance wound closure, collagen deposition, angiogenesis, and growth factor expression while modulating inflammatory responses in preclinical burn wound models, though significant heterogeneity limits immediate clinical application.

This review reports that platelet-rich plasma may be more effective for musculoskeletal conditions when prepared with high platelet doses and low leukocyte content, but further trials are needed to confirm optimal formulations.

This review discusses the potential of exosome therapy for treating diabetic peripheral neuropathy but highlights the need for more robust preclinical trials before clinical application.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This systematic review examines the landscape of cosmetic microneedling using SWOT analysis, identifying strengths like precise delivery and self-administration, while noting challenges such as potential skin damage and regulatory issues, with opportunities in AI-enhanced targeted treatments noted by these researchers.

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

This study evaluated the efficacy of polyphenolic compounds for hair growth in adults with non-scarring alopecia and found that these interventions significantly improved hair density and total area hair count compared to controls, although results were not significantly different from minoxidil.

Transgender women have similar fitness to cisgender women, while transgender men have higher fat and lower strength than cisgender men; hormone therapy affects body composition and strength.

In this systematic review and meta-analysis, researchers found that exosome therapies significantly improved facial wrinkles by 20.2% and enhanced hair density and thickness by 23.6% and 18%, respectively, despite challenges in generalizability due to study heterogeneity and nonstandardized protocols.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This study developed a novel protocol that demonstrated improved localized delivery of minoxidil to eyebrow application sites with minimal runoff, compared to a control formulation.

A new, quick method accurately detects minoxidil in drugs and cosmetics.

This study found that various dietary supplements positively impacted hair density and were well-tolerated among patients with androgenetic alopecia, suggesting they may be useful adjuncts or alternatives to standard treatments.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study analyzed 19 clinical trials and found that dermatologic adverse events, such as rash, xerosis, and mucositis, frequently occur in pediatric patients receiving targeted anticancer therapies.

This systematic review found that hair loss was more frequently observed in acne patients on isotretinoin doses ≥0.5 mg/kg/d compared to those on lower doses, suggesting dose-dependent effects.

This study highlights potential benefits for public health agencies and policymakers in understanding and communicating about PCC symptomatology and experiences.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.